Compare MGIH & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGIH | LEXX |
|---|---|---|
| Founded | 1978 | 2004 |
| Country | Hong Kong | Canada |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4M | 14.5M |
| IPO Year | 2023 | N/A |
| Metric | MGIH | LEXX |
|---|---|---|
| Price | $1.25 | $0.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 46.2K | ★ 1.5M |
| Earning Date | 10-28-2025 | 01-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $25,334,149.00 | $705,923.00 |
| Revenue This Year | N/A | $13.35 |
| Revenue Next Year | N/A | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $1.11 | $0.46 |
| 52 Week High | $4.84 | $2.43 |
| Indicator | MGIH | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 43.39 | 38.76 |
| Support Level | $1.22 | $0.46 |
| Resistance Level | $1.41 | $0.64 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 25.00 | 17.90 |
Millennium Group International Holdings Ltd supplies paper-based packaging solutions, including inner packaging boxes produced with offset or flexo printing and outer corrugated boxes used for transportation, storage, pallets, and point-of-purchase displays. The company manufactures corrugated products of different sizes, shapes, thicknesses, and strengths according to customer specifications. It also operates a supply chain management business in Vietnam to service international clients who source their packaging needs from Vietnam and other ASEAN countries. The corrugated paper is durable, versatile, economical, and lightweight.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.